PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Momentum Building for Novel Vazalore^® Liquid-Filled Aspirin Capsules

SPARTA, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE^®”), announced today certain financial and operational results for the three and 12 months ended December 31, 2021.